These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 8601933)

  • 1. The social contract and the treatment of permanent kidney failure.
    Rettig RA
    JAMA; 1996 Apr; 275(14):1123-6. PubMed ID: 8601933
    [No Abstract]   [Full Text] [Related]  

  • 2. End-stage renal disease therapy: an American success story.
    Friedman EA
    JAMA; 1996 Apr; 275(14):1118-22. PubMed ID: 8601932
    [No Abstract]   [Full Text] [Related]  

  • 3. Is HCFA's reimbursement policy controlling quality of care for end-stage renal disease patients?
    Lockridge RS; McKinney JK
    ASAIO J; 2001; 47(5):466-8. PubMed ID: 11575817
    [No Abstract]   [Full Text] [Related]  

  • 4. Excluded from universal coverage: ESRD patients not covered by Medicare.
    Thamer M; Ray NF; Richard C; Greer JW; Pearson BC; Cotter DJ
    Health Care Financ Rev; 1995; 17(2):123-46. PubMed ID: 10157372
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Medicare HMOs reveal unique contracting strategies for new ESRD risk demonstration.
    Public Sect Contract Rep; 1997 May; 3(5):74-6. PubMed ID: 10174874
    [No Abstract]   [Full Text] [Related]  

  • 6. End-stage renal disease, managed care, and capitation: implications for the renal community.
    Rubin RJ; Gaylin DS; Shapiro JR
    Adv Ren Replace Ther; 1997 Oct; 4(4):306-13. PubMed ID: 9356682
    [No Abstract]   [Full Text] [Related]  

  • 7. The economic cost of ESRD and Medicare spending for alternative modalities of treatment. United States Renal Data System.
    Am J Kidney Dis; 1998 Aug; 32(2 Suppl 1):S118-31. PubMed ID: 9713414
    [No Abstract]   [Full Text] [Related]  

  • 8. Caring for ESRD patients.
    Andriote JM
    Healthplan; 1998; 39(4):33-5. PubMed ID: 10351321
    [No Abstract]   [Full Text] [Related]  

  • 9. Justice and cost-containment in end-stage renal disease.
    Johnstone BV
    J Contemp Health Law Policy; 1987; 3():65-84. PubMed ID: 10301637
    [No Abstract]   [Full Text] [Related]  

  • 10. The graying of dialysis in America.
    Jones FS
    N C Med J; 1996; 57(6):359-62. PubMed ID: 8937160
    [No Abstract]   [Full Text] [Related]  

  • 11. National health insurance: lessons from the United States experiment.
    Derrick FW; Scott CE
    Health Care Manage Rev; 1995; 20(3):55-63. PubMed ID: 7591752
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The ESRD regulatory landscape: a primer & resource. Part 2.
    Robers S
    Nephrol News Issues; 2003 Jan; 17(2):22-5. PubMed ID: 12629824
    [No Abstract]   [Full Text] [Related]  

  • 13. From fee-for-service to capitation: factors driving ESRD reimbursement system change.
    Day LM
    Nephrol News Issues; 1997 Apr; 11(4):22-3, 31. PubMed ID: 9287685
    [No Abstract]   [Full Text] [Related]  

  • 14. Provider-patient relations and treatment choice in the era of fiscal incentives: the case of the end-stage renal disease program.
    Bovbjerg RR; Held PJ; Diamond LH
    Milbank Q; 1987; 65(2):177-202. PubMed ID: 3614141
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Limited resources and the treatment of end-stage renal failure in Britain and the United States.
    Rennie D; Rettig RA; Wing AJ
    Q J Med; 1985 Jul; 56(219):321-36. PubMed ID: 3912791
    [No Abstract]   [Full Text] [Related]  

  • 16. End stage renal disease and Medicare.
    Greer JW
    Health Care Financ Rev; 2003; 24(4):1-5. PubMed ID: 14628396
    [No Abstract]   [Full Text] [Related]  

  • 17. Ethical issues in geriatric nephrology: overview.
    Cummings NB
    Am J Kidney Dis; 1990 Oct; 16(4):367-71. PubMed ID: 2220788
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Re-engineering the ESRD Program amid Medicare reform.
    Neumann ME
    Nephrol News Issues; 2005 Jan; 19(2):40-1. PubMed ID: 15717573
    [No Abstract]   [Full Text] [Related]  

  • 19. Medicare's end-stage renal disease program: current status and future prospects.
    Nissenson AR; Rettig RA
    Health Aff (Millwood); 1999; 18(1):161-79. PubMed ID: 9926654
    [TBL] [Abstract][Full Text] [Related]  

  • 20. What price success?
    Tecnologica; 1996 Nov; ():1-6. PubMed ID: 10179816
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.